AMYLYX PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.775 USD | -3.01% |
|
-3.28% | -87.98% |
Presentation Operator MessageOperator (Operator)Good afternoon. My name is Debbie, and I will ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.
Sector
Pharmaceuticals
Calendar
2024-06-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
1.83
USD
Average target price
4.083
USD
Spread / Average Target
+123.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -87.98% | 124M | |
| -1.62% | 89.22B | |
| +1.32% | 40.49B | |
| -15.80% | 32.79B | |
| +64.13% | 26.23B | |
| -21.50% | 14.52B | |
| -8.09% | 13.09B | |
| -44.07% | 11.6B | |
| -13.06% | 11.5B | |
| +4.94% | 8.82B |
- Stock Market
- Equities
- AMLX Stock
- News Amylyx Pharmaceuticals, Inc.
- Transcript : Amylyx Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 11, 2023
